Skip to content

Evaluation of Cannabidiol effect in treatment of patients with Obsessive-Compulsive Disorder

Evaluation of Cannabidiol effect as adjunctive therapy on symptoms of patients with Obsessive-Compulsive Disorder

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210310050660N1
Enrollment
40
Registered
2021-04-01
Start date
2021-04-04
Completion date
Unknown
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: Intervention group: In addition to standard treatment, 25 mg of cannabidiol drop were administered orally daily for 8 weeks. Intervention 2: Control group: In addition to standard trea

Sponsors

Qazvin University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Being healthy Obssesive compulsive disorder (OCD) diagnosis through DSM-5 criteria ( DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, 5TH EDITION) Achieving at least score 16 according to YALE BROWN OBSSESIVE COMPLUSIVE SCORE ( YBOS) Being only on SSRIs through recent 4 weeks Do not have history of using cannabis or other ilicit drugs

Exclusion criteria

Exclusion criteria: Unwilling to participate in this study Having history of other psychiatric disorder including psychotic, cognitive and substance use disorder Being medically ill that cause more side effects than usual Pregnancy, expecting to being pregnant and lactation Achieving score more than 17 through completing Beck Depression scale before starting study

Design outcomes

Primary

MeasureTime frame
Intensity of obsessive-compulsive disorder. Timepoint: Before entering into study, in week 4 and 8. Method of measurement: Yale–Brown Obsessive Compulsive Scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahnaz Majidi

Qazvin University of Medical Sciences

Mahnaz.majidi@yahoo.com+98 28 3369 9022

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026